Patient Recruitment Paper

Decent Essays

Patient Recruitment
To recruit patients for the clinical trial, the researchers need to clearly define the target population and find the accessible sources of population. A validity study relies on the adequate sample size. Without enough recruitment and sufficient power, there’s an increased chance of type II error. The recruitment rate is influenced by both patient and researcher. The study of Barriers and opportunities for enhancing patient recruitment and retention in clinical research: findings from an interview study in an NHS academic health science center (Adams et al., 2015) conducted a qualitative study on the barriers and opportunities for enhancing patient recruitment. Open-ended, one-to-one interviews were utilized with 11 purposive …show more content…

It involves years of experiment and observation in clinical research. Trial of drug sometimes involves patient with specific health conditions who are willing to participant a new treatment, sometimes are healthy individuals. The safety and efficacy be tested from phase I to phase IV. The study of efficacy and safety of Roxadustat for treatment of anemia, we observed and assisted field work, Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that regulates iron metabolism and stimulates erythropoiesis. Phase II trials have done on Roxadustat. In the clinical trial of Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients, ( Besarab et al., 2015) it conducted a multicenter and randomized phase II study on Roxadustat in subjects with anemia and stage 3or 4 chronic kidney disease. The treatment period is 4 weeks and up to 12 weeks follow-up period. 116 subjects were randomized receive Roxadustat treatment (n=88) and placebo (n=28). Roxadustat increased the Hb concentration in subjects, the Hb response were promoted. In the Roxadustat study, the median time to increase Hb ≥1 g/dL was 21 days, which is shorter than the EPO analogues treatment which is range from 26 days to 43 days. The advanced effects were similar in Roxadustat and placebo and were the most common Advanced effects in chronic kidney disease

Get Access